Craft

Voyager Therapeutics

Stock Price

$8.9

2023-09-11

Market Capitalization

$390.7 M

2023-09-11

Revenue

$40.9 M

FY, 2022

Voyager Therapeutics Summary

Company Summary

Overview
Voyager Therapeutics is a gene therapy company developing treatments for diseases of the central nervous system (CNS). It offers therapies for such diseases as Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis, and Friedreich’s ataxia.
Type
Public
Status
Active
Founded
2014
HQ
Cambridge, MA, US | view all locations
Website
https://voyagertherapeutics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Al Sandrock

    Al Sandrock, Chief Executive Officer

  • Allen Nunnally

    Allen Nunnally, Chief Business Officer

  • Robin Swartz

    Robin Swartz, Chief Operating Officer

  • Michelle Quinn Smith

    Michelle Quinn Smith, Chief Human Resources Officer

Operating MetricsView all

Patent Applications

351
4.6%

FY, 2021

Patents Issued

229
15.1%

FY, 2021

LocationsView all

1 location detected

  • Cambridge, MA HQ

    United States

    64 Sidney St

Voyager Therapeutics Financials

Summary Financials

Revenue (Q2, 2023)
$4.9M
Net income (Q2, 2023)
($22.2M)
Cash (Q2, 2023)
$244.3M
EBIT (Q2, 2023)
($25.4M)
Enterprise value
$168.2M

Footer menu